IDD-3 is a cellular therapeutic vaccine consisting of autologous monocyte-derived matured DC, generated from a single apheresis of peripheral blood mononuclear cells (PBMC), cultured in serum-free medium in the presence of the cytokines granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin-13 (IL-13) and pulsed with tumor lysates produced from three allogeneic melanoma cell lines [3,4]. Here, IL13 is linked to neoplasm.